Adupa P Rao, MD

Dr. Rao attended the University of Southern California as an undergraduate before returning to his native India for medical school. After receiving his medical degree, Dr. Rao was welcomed back to USC and completed an internship, a residency and two fellowships at the LAC+USC Medical Center. An expert in Cystic Fibrosis, Dr. Rao has taught several courses to medical students on understanding the disease and is the Associate Director of the Keck School of Medicine’s Adult Cystic Fibrosis Program.

Dr. Rao’s research activities include lung transplantation and Cystic Fibrosis: Testosterone, Rate of PFT Decline. He has also been a distinguished lecturer on Sarcoidosis and created a DVD produced by the Cystic Fibrosis Foundation titled “Looking Ahead: Transition for Pediatric to Adult Cystic Fibrosis Patient Care.”

• Pasadena Magazine: Top Doctor, 2011
• GlaxoSmithKline: Fellowship Research Award, 2001
• Resident of the Year, 1998
• Chief Resident of Internal Medicine, 1998
• Tutor of the Year, 1987

• Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients Pharmaceutics. 2023 May 08; 15(5). . View in PubMed
• Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series Pharmacotherapy. 2023 04; 43(4):291-299. . View in PubMed
• Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19 Clin Pharmacol Ther. 2022 06; 111(6):1324-1333. . View in PubMed
• Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis Antimicrob Agents Chemother. 2018 09; 62(9). . View in PubMed
• Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis Antimicrob Agents Chemother. 2017 10; 61(10). . View in PubMed
• Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation Antimicrob Agents Chemother. 2017 08; 61(8). . View in PubMed
• Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells Pulm Pharmacol Ther. 2012 Oct; 25(5):377-82. . View in PubMed
• GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis J Cyst Fibros. 2009 Jan; 8(1):19-25. . View in PubMed
• Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine J Clin Pharmacol. 2008 Aug; 48(8):957-65. . View in PubMed

• Beringer, Paul